Figure 8.

Proposed algorithm for the management of patients with suspected AIH and concurrent alcohol-associated liver disease (A, adapted from ref. 45) or MASLD (B, adapted from ref. 63)

ALD, alcohol-associated liver disease; γ-GT, gamma-glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AIH, autoimmune hepatitis; F, female; M, male; IgG, immunoglobulin G; ULN, upper limit of normal; AUD, alcohol use disorder; CPGs, clinical practice guidelines; MASLD, metabolic dysfunction-associated steatotic liver disease; AZA, azathioprine; MMF, mycophenolate mofetil; MetS, metabolic syndrome